Cytek Biosciences (CTKB) Earnings Analysis
Cytek Biosciences (CTKB) has no confirmed upcoming earnings date. Last quarter (2026-05-07) it missed with EPS -0.12 USD vs -0.08 USD est (-50%). It has beaten estimates in 2/3 recent quarters (67%). Trailing P/E -7.87.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does CTKB next report earnings?
No confirmed upcoming earnings date is currently scheduled for CTKB. This page updates as the calendar is published.
CTKB earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-07 | -0.12 USD | -0.08 USD | -50% | Miss |
| 2026-02-26 | -0.01 USD | -0.02 USD | +50% | Beat |
| 2025-02-27 | 0.07 USD | 0.05 USD | +40% | Beat |
Beat rate: 2/3 (67%) over reported quarters with consensus data.
CTKB valuation and analyst view
| Trailing P/E | -7.87 |
|---|---|
| Trailing EPS | -0.57498 USD |
| Price / book | 1.78 |
| Dividend yield | 0.00% |
| Market cap | 0.59B |
| Analyst consensus | Buy (3 buy / 1 hold / 1 sell) |
| Avg price target | 5.13 USD |
Related research pages
Frequently asked questions
When is Cytek Biosciences (CTKB)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for CTKB. This page updates as the calendar is published.
Did CTKB beat earnings last quarter?
In its 2026-05-07 report, CTKB posted EPS of -0.12 USD versus a -0.08 USD estimate — a miss of 50%.
What is CTKB's earnings track record?
Over the last 3 reported quarters with consensus data, CTKB beat estimates 2 times (67%).
What is CTKB's current P/E ratio and EPS?
CTKB trades at a trailing P/E of -7.87 on trailing EPS of -0.574981841799476 USD.
What do analysts rate CTKB?
Analyst consensus is "Buy" across 5 ratings (0 strong buy, 3 buy, 1 hold, 1 sell, 0 strong sell). Average 12-month price target: 5.13 USD.